Fortress Biotech Announces Receipt Of Notice Of Option Exercise From AstraZeneca To Fully Acquire Caelum Biosciences, A Company Founded By Fortress Biotech; Option Triggers Upfront Payment Of $150M To Caelum, Of Which $64M Is Payable To Fortress